Finding new osteoarthritis medicines via AI and genetics
The new drug is a starting point for therapies that treat OA at its source. Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of… read more.
The new drug is a starting point for therapies that treat OA at its source. Osteoarthritis (OA) is a chronic, painful joint disease and a leading cause of… read more.
Having high blood pressure is associated with greater intentions to follow doctors’ recommendations to take medication than people without high blood pressure but lesser intentions to make recommended… read more.
The first evidence that night work and chronic insomnia may increase the risk of developing long COVID comes from a new study led by ISGlobal, a centre supported by “la Caixa” Foundation,… read more.
Merck BioPharma K.K., the Japanese subsidiary of Merck KGaA, began participant registration for a Phase III trial evaluating the efficacy and safety of fixed-dose combinations of follitropin alfa… read more.
The MHRA has approved Romvimza (vimseltinib ) to treat adult patients with tenosynovial giant cell tumour (TGCT) when it impacts movement or where surgery is not an option. TGCT (Giant cell… read more.
Neck and back pain could be caused by changes in gene activity that trigger the breakdown of the spine’s natural shock absorbers, new research suggests. Findings from a… read more.
Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial… read more.
Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie’s disease treated with Xiaflex (collagenase clostridium… read more.
Emily P. Hyle, MD, and Kenneth A. Freedberg, MD, of the Medical Practice Evaluation Center within the Department of Medicine at Mass General Brigham, are the lead and senior authors of a… read more.
Bristol Myers Squibb announced that the FDA has approved ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple… read more.
Daiichi Sankyo and AstraZeneca announced that Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in China for the first-line treatment of adult patients with unresectable or… read more.
A multi-institutional study led by researchers at Children’s Hospital of Philadelphia (CHOP) found that telemedicine is becoming increasingly common for problem-based primary care, particularly for children with endocrine… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.